Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka d.d., novo mesto (slovėnija) - injekcinė emulsija - 1 ml injekcinės emulsijos yra:retinolio palmitato (vit. a)–50 000 tv, cholekalciferolio (vit. d3)–25 000 tv, alfa-tokoferilio acetato (vit. e) –20 mg. - galvijams, veršeliams, arkliams, kumeliukams, kiaulėms, paršeliams, avims, ėriukams, ožkoms, ožkiukams, triušiams, šunims ir katėms augimui ir produktyvumui stimuliuoti, atsparumui infekcinėms ligoms didinti, bendrai organizmo būklei gerinti, mažinti stresą transportuojant, pakeitus laikymo vietą ar kt., vitaminų trūkumo ligoms gydyti ir profilaktiškai, esant mitybiniam sterilumui, sveikstant, sergant rachitu ar osteomaliacija, sutrikus maitinimuisi.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

norgine b.v. - geležies maltolis - anemija, geležies trūkumas - antianeminiai preparatai - feraccru yra nurodyta suaugusiųjų gydymas geležies trūkumas.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka d.d., novo mesto (slovėnija) - geriamojo tirpalo milteliai - vitamin a (retinyl acetate) - 2 000 00 iu; vitamin d3 (cholecalciferol) - 100 000 iu; vitamin e (tocopheryl acetate) - 550 iu; vitamin c (ascorbic acid) - 2 000.0 mg; vitamin k3 (menadione sodium bisulphite) - 200.0 mg; vitamin b1 (thiamine hydrochloride) - 150.0 mg; vitamin b2 (riboflavine sodium phosphate) - 250.0 mg; vitamin b6 (pyridoxine hydrochloride) - 200.0 mg; vitamin b12 (cyanocobalamine) - 1.0 mg; nicotinamide - 1 800.0 mg; calcium d-pantothenate - 650.0 mg; selenium (as sodium selenite) - 3.0 mg; excipients - paukščiams, kiaulėms, galvijams, avims, ožkoms, arkliams ir triušiams padidėjus vitaminų ir seleno poreikiui, kepenų ir raumeninio audinio medžiagų apykaitos sutrikimų profilaktikai.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabriko liga - kiti virškinimo trakto ir metabolizmo produktus, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

teva b.v. - clopidogrel (as hydrogen sulfate) - myocardial infarction; acute coronary syndrome; peripheral vascular diseases; stroke - antitromboziniai vaistai - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. suaugusiems pacientams, kenčiantiems nuo ūminio vainikinių arterijų sindromo:ne-st segmento pakilimu ūminis vainikinių arterijų sindromas (nestabili krūtinės angina ar ne q bangos miokardo infarktu), įskaitant pacientus, kuriems atliekama stento krovos po perkutaninės vainikinių intervencijos, kartu su acetilsalicilo rūgštimi (asr). st segmento pakilimu ūmus miokardo infarktas, kartu su asr medikamentais gydytų pacientų, atitinkančių trombolizinė terapija. prevencijos atherothrombotic ir thromboembolic įvykių prieširdžių fibrillationin suaugusiems pacientams, sergantiems prieširdžių virpėjimas, kurie turi mažiausiai vieną rizikos veiksnys širdies ir kraujagyslių įvykių, nėra tinkamas gydymas vitamino k antagonistais (vka), ir kas yra maža kraujavimo rizika, klopidogrelio yra nurodytas kartu su asa prevencijos atherothrombotic ir thromboembolic renginių, įskaitant insultą.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

orion corporation - entakaponas - parkinsono liga - anti-parkinsono vaistai - entacapone skiriamas kaip papildoma standartinė levodopos preparatai / benserazido arba levodopos / karbidopa vartoti pacientams, sergantiems parkinsono liga ir dozės pabaigos motorinės svyravimus, kurie negali būti stabilizuota tų derinių.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinsono liga - nervų sistema - levodopos/carbidopa/entacapone orion yra skirtas gydyti suaugusiems pacientams, sergantiems parkinsono liga bei dozės pabaigos motorinės svyravimai ne stabilizuota levodopos / dopadekarboksilazės (ddc)-inhibitoriais.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

csl behring gmbh - žmogaus normalus imunoglobulinas (scig) - imunologinių trūkumų sindromai - imuninės serumai ir imunoglobulinai, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

viatris limited - klopidogrelio besilatas - peripheral vascular diseases; stroke; myocardial infarction - antitromboziniai vaistai - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmento pakilimu ūmus miokardo infarktas, kartu su asr medikamentais gydytų pacientų, atitinkančių trombolizinė terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. daugiau informacijos, skaitykite skyrių 5.